Pablo Berlanga

Pablo Berlanga MD, PhD, is a paediatric oncologist at Gustave Roussy Cancer Campus, involved in early-phase pediatric clinical trials and precision medicine. He is a member of the ITCC and SIOPEN.

He trained in paediatric oncology at the Hospital La Fe Hospital in Valencia, Spain and then worked as a paediatric oncology consultant until 2017 when he moved to the Children and Adolescent Oncology Department at Gustave Roussy (France). He is actively involved in paediatric phase I/II trials and precision medicine program, bone sarcomas and neuroblastoma. He is member of the ITCC Solid Tumour Steering Committee and he is the current Chair of the SIOPEN Educational Committee.

His main research interest are the incorporation of new therapies to upfront therapy and he is the coordinating investigator of chemo-immunotherapy arm for patients with insufficient metastatic response after induction chemotherapy within the HRNBL2 trial and the Principal Investigator of the phase Ib REGO-INTER-EWING (regorafenib in combination with conventional first line treatment for patients with multimetastatic Ewing sarcoma). He is also interested in real-world data on innovative anticancer therapies prescribed outside their marketing authorization or through compassionate use programs and he is the Principal Investigator of the SACHA study (Secured Access to innovative medicines for CHildren with cAncer, NCT04477681).